City Therapeutics Announces Upsized $230 Million IPO
Washington, DC – October 19, 2026 – Cooley advised the underwriters of City Therapeutics, Inc., a clinical-stage biotechnology company developing the next generation of RNA interference therapeutics, in connection with City’s upsized $230 million initial public offering (IPO). City issued 12,777,777 shares of its common stock at a price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. City’s common stock began trading on the Nasdaq Global Market on October 16, 2026, under the ticker symbol CTY.
Goldman Sachs & Co. LLC, Jefferies and Stifel acted as joint bookrunning managers for the offering. Oppenheimer & Co. also acted as a joint bookrunning manager for the offering.
Lawyers Darah Protas, Evan Leitner, Div Gupta, Richard Segal, and Jayne Munger led the Cooley team advising the underwriters.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.